Journal of Neurogastroenterology and Motility

The Korean Society of Neurogastroenterology and Motility (대한소화기 기능성질환 운동학회)
권호 표지
DOI QR코드

DOI QR Code

The Effect of Trimebutine on the Overlap Syndrome Model of Guinea Pigs

  • Hussain, Zahid (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Jung, Da Hyun (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Lee, Young Ju (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Park, Hyojin (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine)
  • Received : 2018.03.03
  • Accepted : 2018.06.12
  • Published : 2018.10.30
⟨ Previous Next ⟩

Abstract

Background/Aims Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common gastrointestinal (GI) disorders and these patients frequently overlap. Trimebutine has been known to be effective in controlling FD co-existing diarrhea-dominant IBS, however its effect on overlap syndrome (OS) patients has not been reported. Therefore, we investigated the effect of trimebutine on the model of OS in guinea pigs. Methods Male guinea pigs were used to evaluate the effects of trimebutine in corticotropin-releasing factor (CRF) induced OS model. Different doses (3, 10, and 30 mg/kg) of trimebutine were administered orally and incubated for 1 hour. The next treatment of $10{\mu}g/kg$ of CRF was intraperitoneally injected and stabilized for 30 minutes. Subsequently, intragastric 3 mL charcoal mix was administered, incubated for 10 minutes and the upper GI transit analyzed. Colonic transits were assessed after the same order and concentrations of trimebutine and CRF treatment by fecal pellet output assay. Results Different concentrations (1, 3, and $10{\mu}g/kg$) of rat/human CRF peptides was tested to establish the OS model in guinea pigs. CRF $10{\mu}g/kg$ was the most effective dose in the experimental OS model of guinea pigs. Trimebutine (3, 10, and 30 mg/kg) treatment significantly reversed the upper and lower GI transit of CRF induced OS model. Trimebutine significantly increased upper GI transit while it reduced fecal pellet output in the CRF induced OS model. Conclusions Trimebutine has been demonstrated to be effective on both upper and lower GI motor function in peripheral CRF induced OS model. Therefore, trimebutine might be an effective drug for the treatment of OS between FD and IBS patients.

Keywords

Acknowledgement

Supported by : Samil Pharmaceuticals

References

  1. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010;8:401-409. https://doi.org/10.1016/j.cgh.2009.07.020
  2. Kaji M, Fujiwara Y, Shiba M, et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol 2010;25:1151-1156. https://doi.org/10.1111/j.1440-1746.2010.06249.x
  3. Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003;98:2454-2459. https://doi.org/10.1111/j.1572-0241.2003.07699.x
  4. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995;109:671-680. https://doi.org/10.1016/0016-5085(95)90373-9
  5. Caballero-Plasencia AM, Sofos-Kontoyannis S, Valenzuela-Barraco M, Martin-Ruiz JL, Casado-Caballero FJ, Lopez-Manas JG. Irritable bowel syndrome in patients with dyspepsia: a community-based study in southern Europe. Eur J Gastroenterol Hepatol 1999;11:517-522. https://doi.org/10.1097/00042737-199905000-00009
  6. Mayer EA, Craske M, Naliboff BD. Depression, anxiety, and the gastrointestinal system. J Clin Psychiatry 2001;8(suppl 8):28-36; discussion 37.
  7. Levy RL, Olden KW, Naliboff BD, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 2006;130:1447-1458. https://doi.org/10.1053/j.gastro.2005.11.057
  8. Corsetti M, Caenepeel P, Fischler B, Janseens J, Tack J. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol 2004;99:1152-1159. https://doi.org/10.1111/j.1572-0241.2004.30040.x
  9. Tack J, Demedts I, Dehondts G, et al. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002;122:1738-1747. https://doi.org/10.1053/gast.2002.33663
  10. Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology 2011;140:761-765. https://doi.org/10.1053/j.gastro.2011.01.032
  11. Caso JR, Leza JC, Menchen L. The effects of physical and psychological stress on the gastrointestinal tract: lessons from animal models. Curr Mol Med 2008;8:299-312. https://doi.org/10.2174/156652408784533751
  12. Tache Y, Martinez V, Million M,Wang L. Stress and the gastrointestinal tract. III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am J Physiol Gastrointest Liver Physiol 2001;280:G173-G177. https://doi.org/10.1152/ajpgi.2001.280.2.G173
  13. Tache Y, Martinez V, Wang L, Million M. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol 2004;141:1321-1330. https://doi.org/10.1038/sj.bjp.0705760
  14. Tache Y, Perdue MH. Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function. Neurogastroenterol Motil 2004;16(suppl 1):137-142. https://doi.org/10.1111/j.1743-3150.2004.00490.x
  15. Williams CL, Peterson JM, Villar RG, Burks TF. Corticotropinreleasing factor directly mediates colonic responses to stress. Am J Physiol 1987;253(4 Pt 1):G582-G586.
  16. Martinez V, Wang L, Rivier JE, Vale W, Tache Y. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther 2002;301:611-617. https://doi.org/10.1124/jpet.301.2.611
  17. Maillot C, Million M, Wei JY, Gauthier A, Tache Y. Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats. Gastroenterology 2000;119:1569-1579. https://doi.org/10.1053/gast.2000.20251
  18. Hussain Z, Kim HW, Huh CW, Lee YJ, Park H. The effect of peripheral CRF peptide and water avoidance stress on colonic and gastric transit in guinea pigs. Yonsei Med J 2017;58:872-877. https://doi.org/10.3349/ymj.2017.58.4.872
  19. Nagasaki, M., Komori, S., and Ohashi, H. Effect of trimebutine on voltage-activated calcium current in rabbit ileal smooth muscle cells. Br J Pharmacol 1993;110:399-403. https://doi.org/10.1111/j.1476-5381.1993.tb13823.x
  20. Lee HT, Kim BJ. Trimebutine as a modulator of gastrointestinal motility. Arch Pharm Res 2011;34:861-864. https://doi.org/10.1007/s12272-011-0600-7
  21. Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res 1997; 25:225-246. https://doi.org/10.1177/030006059702500501
  22. Roman FJ, Lanet S, Hamon J, et al. Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J Pharmacol Exp Ther 1999;289:1391-1397.
  23. Cenac N, Castro M, Desormeaux C, et al. A novel orally administered trimebutine compound (GIC-1001) is anti-nociceptive and features peripheral opioid agonistic activity and hydrogen sulphide-releasing capacity in mice. Eur J Pain 2016;20:723-730. https://doi.org/10.1002/ejp.798
  24. Won KJ, Sanders KM, Ward SM. Interstitial cells of Cajal mediate mechanosensitive responses in the stomach. Proc Natl Acad Sci USA 2005;102:14913-14918. https://doi.org/10.1073/pnas.0503628102
  25. Morisawa T, Hasegawa J, Tanabe K, Watanabe A, Kitano M, Kishimoto Y. Effects of trimebutine maleate on delayed rectifier K+ currents in guinea-pig ventricular myocytes. J Pharm Pharmacol 2000;52:403-408. https://doi.org/10.1211/0022357001774156
  26. Nastaskin I, Mehdikhani E, Conklin J, Park S, Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci 2006;51:2113-2120. https://doi.org/10.1007/s10620-006-9306-y
  27. Wang A, Liao X, Xiong L, et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol 2008;8:43. https://doi.org/10.1186/1471-230X-8-43
  28. Lee HJ, Lee SY, Kim JH, et al. Depressive mood and quality of life in functional gastrointestinal disorders: differences between functional dyspepsia, irritable bowel syndrome and overlap syndrome. Gen Hosp Psychiatry 2010;32:499-502. https://doi.org/10.1016/j.genhosppsych.2010.05.002
  29. Park JM, Choi MG, Cho YK, et al. Functional gastrointestinal disorders diagnosed by Rome III questionnaire in Korea. J Neurogastroenterol Motil 2011;17:279-286. https://doi.org/10.5056/jnm.2011.17.3.279
  30. Park H. Functional gastrointestinal disorders and overlap syndrome in Korea. J Gastroenterol Hepatol 2011;26(suppl 3):12-14.
  31. Chaussade S, Grandjouan S, Couturier D, Thierman-Duffaud D, Henry JF. Induction of phase III of the migrating motor complex in human small intestine by trimebutine. Eur J Clin Pharmacol 1987;32:615-618. https://doi.org/10.1007/BF02455998
  32. Vantrappen G, Peeters T. Motilin. In: Schultz SG, ed. Handbook of physiology. The gastrointestinal system. Vol. II. Bethesda MD: American Physiological Society 1989:545-558.
  33. Romanski KW. Importance of the enteric nervous system in the control of the migrating motility complex. Physiol Int 2017;104:97-129. https://doi.org/10.1556/2060.104.2017.2.4
  34. Raehal KM, Bohn LM. Mu opioid receptor regulation and opiate responsiveness. AAPS J 2005;7:E587-E591. https://doi.org/10.1208/aapsj070360
  35. Valori R, Shannon S, Reddy N, Deniel EE, Sollins SM. The action of trimebutine maleate on gastrointestinal motility is mediated by opiate receptors in human subjects. Gastroenterol Clin BioI 1987;11(3 Pt 2):102B-104B.
  36. Lordal M, Hellstrom PM. Serotonin stimulates migrating myoelectric complex via 5-HT3 receptors dependent on cholinergic pathways in rat small intestine. Neurogastroenterol Motil 1999;11:1-10. https://doi.org/10.1046/j.1365-2982.1999.00125.x
  37. Diop L, Pascaud X, Le Gallou B, Junien JL. Travel stress alters the intestinal myoelectric complex in rats: antagonistic effect of trimebutine. Life Sci 1992;50:263-271. https://doi.org/10.1016/0024-3205(92)90333-K
  38. Valori RM, Kumar D, Wingate DL. Effects of different types of stress and "prokinetic" drugs on the control of the fasting motor complex in humans. Gastroenterology 1986;90:1890-1900. https://doi.org/10.1016/0016-5085(86)90258-1
  39. Distrutti E, Mencarelli A, Renga B, et al. A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. Pharmacol Res 2009;59:319-329. https://doi.org/10.1016/j.phrs.2009.01.008
  40. Wallace J, Cirino G, Santagada V, Caliendo G. Salts of trimebutine and n-desmethyl trimebutine. Washington DC: US Patent and Trademark Office 2010.
  41. Wei HJ, Xu JH, Li MH, et al. Hydrogen sulfide inhibits homocysteineinduced endoplasmic reticulum stress and neuronal apoptosis in rat hippocampus via upregulation of the BDNF-TrkB pathway. Acta Pharmacol Sin 2014;35:707-715. https://doi.org/10.1038/aps.2013.197

Cited by

  1. The Effect of Trimebutine and/or Helicobacter pylori Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders vol.25, pp.3, 2018, https://doi.org/10.5056/jnm19033
  2. Trimebutine: a state-of-the-art review vol.65, pp.3, 2019, https://doi.org/10.23736/s1121-421x.19.02567-4
  3. Rol de los antiespasmódicos en el manejo del síndrome de intestino irritable vol.34, pp.3, 2019, https://doi.org/10.22516/25007440.309
  4. Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial vol.56, pp.7, 2018, https://doi.org/10.3390/medicina56070339
  5. Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia vol.27, pp.2, 2018, https://doi.org/10.5056/jnm20175
  6. Good to Know: Baseline Data on Feed Intake, Fecal Pellet Output and Intestinal Transit Time in Guinea Pig as a Frequently Used Model in Gastrointestinal Research vol.11, pp.6, 2018, https://doi.org/10.3390/ani11061593